The task force has called them false positives, which is not a correct term. We're not telling a woman when she's recalled from screening that she has cancer; we're simply telling her she needs some more imaging to identify if there's an abnormality. Over 94% or 95% of those turn out to be overlapping tissue. We're looking at a three-dimensional structure and showing it in 2-D, and it's something we can use to reassure a woman at that time.
We need to do biopsies, and about 1% or less are benign. This is a very well-tolerated procedure. I do biopsies all the time, and women tell me they would much rather have this kind of abnormal imaging test than have a delayed diagnosis of breast cancer. The women who have a delayed late-stage diagnosis are angry that they lost the opportunity to be screen-detected.